RU58841 — Safety, Research, Risks & Legal Status

Not medical advice. RU58841 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	RU-58841, Fluasterone, Andriol
Category	Research Chemical
origin	Developed in France; never registered as pharmaceutical
topical_vehicle	Various formulations (ethanol, propylene glycol); stability variable
US legal status	Not FDA-approved for any indication. Sold as a research chemical for hair loss. No approved pharmaceutical product anywhere. Regulatory status unclear; not scheduled but unapproved.

What is RU58841?

Nonsteroidal androgen receptor antagonist designed to selectively block androgen effects in hair follicles. Not a SARM; mechanism is androgenic blockade in scalp tissue only. Topical research compound for pattern hair loss.

How it works

Nonsteroidal androgen receptor antagonist; blocks androgen signaling in dermal papilla and hair follicle cells without systemic hormonal effects (intended). Selectivity and tissue distribution in humans unknown.

Background & history

Developed in France in 1970s-1980s for androgenetic alopecia. Early human feasibility studies conducted; development discontinued. Available only as unregulated research chemical in certain markets.

What the research says

Limited human evidence from small, non-controlled studies. Mostly preclinical and animal research showing androgen blockade in hair follicles. No large randomized trials. Comparison to finasteride or minoxidil shows less robust evidence.

Reported effects

Reported androgenic blockade in hair follicle tissue (preclinical)
Small human studies suggest potential hair loss slowing
Topical application intended to minimize systemic exposure
Limited human efficacy data vs approved alternatives
Mechanism distinct from 5-alpha reductase inhibitors

Dosing & administration (informational)

Early studies employed topical application at concentrations of 1-5 percent in various vehicles. No standardized dosing protocol established or validated.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Limited human safety data; small trial populations only
Topical absorption and systemic exposure levels unknown
Potential for androgenic feedback or endocrine disruption unclear
Unverified product formulation and quality typical
No approved comparator; efficacy/risk profile unvalidated
Self-use without medical oversight carries unknown risks

Drug & supplement interactions

Topical androgen blockade may interact with systemic androgens or endocrine-active compounds
Unknown interaction with dermal microbiota or skin pH regulators
Possible synergism with topical minoxidil; clinical data absent
Absorption enhancement from penetration enhancers not characterized

Who should avoid it

In individuals with scalp infections or dermatological conditions
With other topical androgenic agents or hair-treatment compounds
During pregnancy or breastfeeding (systemic exposure and fetal effects unknown)
If history of androgenic feedback disruption or endocrine sensitivity

How it is commonly combined

Topical combination with minoxidil or finasteride is anecdotal; efficacy or safety of combinations completely unvalidated.

Legal & regulatory. Not FDA-approved for any indication. Sold as a research chemical for hair loss. No approved pharmaceutical product anywhere. Regulatory status unclear; not scheduled but unapproved.

Quality & harm reduction

D
e
m
a
n
d
a
n
a
l
y
t
i
c
a
l
v
e
r
i
f
i
c
a
t
i
o
n
o
f
R
U
-
5
8
8
4
1
i
d
e
n
t
i
t
y
a
n
d
c
o
n
c
e
n
t
r
a
t
i
o
n
.
C
h
e
c
k
f
o
r
s
o
l
v
e
n
t
p
u
r
i
t
y
a
n
d
s
t
a
b
i
l
i
t
y
o
f
f
o
r
m
u
l
a
t
i
o
n
;
v
e
r
i
f
y
s
t
e
r
i
l
i
t
y
a
n
d
a
b
s
e
n
c
e
o
f
c
o
n
t
a
m
i
n
a
n
t
s
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Is RU-58841 approved for hair loss?

No. Not FDA-approved or approved anywhere. Sold as 'research chemical' only; efficacy and safety unproven in robust trials.

How does it work differently from finasteride?

Topical androgen receptor blockade vs finasteride's systemic 5-alpha reductase inhibition. RU-58841 evidence is far weaker.

Can it cause systemic side effects?

Unclear. Topical application intended to minimize systemic exposure, but absorption and effects unknown.

Why not just use finasteride or minoxidil?

Both are FDA-approved with robust evidence. RU-58841 is experimental and unproven by comparison.

What is the evidence quality?

Small, non-randomized human studies only; no large controlled trials. Preclinical research more robust than clinical data.

References & further reading

PubMed historical French language studies on RU-58841 and androgenetic alopecia
Finasteride and minoxidil FDA approval and evidence-based efficacy data for comparison
Dermatology literature on nonsteroidal androgen receptor antagonist mechanisms